Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2013 - 2026)

Rigel Pharmaceuticals' Other Operating Expenses history runs 13 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 4.47% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 5.77% decrease from a year earlier, with the FY2025 full-year figure at $19.6 million, up 5.22% from the prior year.
• Other Operating Expenses fell to $4.6 million in Q1 2026 per RIGL's latest filing, from $6.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $14.5 million in Q4 2022 and bottomed at $121000.0 in Q1 2022.
• The 5-year median for Other Operating Expenses is $3.8 million (2023), against an average of $3.9 million.
• Biggest YoY gain for Other Operating Expenses was 707.44% in 2023; the steepest drop was 73.91% in 2023.
• Year by year, Other Operating Expenses stood at $14.5 million in 2022, then tumbled by 73.91% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then advanced by 2.87% to $6.0 million in 2025, then retreated by 22.65% to $4.6 million in 2026.
• Per Business Quant, the three latest RIGL Other Operating Expenses figures stand at $4.6 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025).